BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) had its target price lowered by Guggenheim from $50.00 to $46.00 in a report issued on Tuesday, The Fly reports. Other equities analysts have also issued reports about the company. Jefferies Financial Group lowered BioXcel Therapeutics from a buy rating to a hold rating and increased their price target […]